Postrecurrence Survival After Liver Transplantation for Liver Metastases From Neuroendocrine Tumors
| Autor: | Jorgelina Coppa, Massimo Milione, Sherrie Bhoori, Roberta Elisa Rossi, Carlo Sposito, Marco Bongini, Vincenzo Mazzaferro, M. Monteleone |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Carcinoma Hepatocellular medicine.medical_treatment Neuroendocrine tumors Liver transplantation Gastroenterology Peritoneum Interquartile range Internal medicine medicine Overall survival Humans Single institution Surgical treatment Retrospective Studies Transplantation business.industry Liver Neoplasms medicine.disease Primary tumor Liver Transplantation Neuroendocrine Tumors Treatment Outcome medicine.anatomical_structure Neoplasm Recurrence Local business |
| Zdroj: | Transplantation. 105:2579-2586 |
| ISSN: | 0041-1337 |
| Popis: | BACKGROUND Liver metastases from neuroendocrine tumors (NETs) are an accepted indication for liver transplantation (LT). Despite strict patient selection, post-LT recurrence is observed in 30%-50% of cases. Postrecurrence survival is poorly investigated as well as factors influencing postrecurrence outcomes. METHODS Consecutive patients treated at a single institution for post-LT recurrence of NET between January 1, 2004, and December 31, 2018, were included. Baseline patients' characteristics, data on the primary tumor, pretransplant therapies, posttransplant recurrence and treatments, and long-term outcomes were prospectively collected and retrospectively analyzed. RESULTS Thirty-two patients presented with post-LT NET recurrence occurring 82.9 mo (interquartile range, 29.4-119.1 mo) from LT, and the most common sites were abdominal lymph nodes (59.4%), peritoneum (6.3%), and lungs (6.3%). Fourteen patients (43.8%) underwent surgery with radical intent. Five- and 10-y survival after recurrence were 76.3% and 45.5%, respectively. Only time from LT to recurrence had a significant impact on postrecurrence survival, being 5-y overall survival 89.5% versus 0% for patients recurring >24 mo after LT versus ≤24 mo, respectively (P = 0.001). Moreover, for patients with Ki-67 monoclonal antibody staining >2% at recurrence, 5 y overall survival was 87.5% versus 0% for those undergoing surgery versus locoregional or systemic treatments (P = 0.011). CONCLUSIONS The presented results, although based on a retrospective and relatively small series, show that excellent long-term survival is observed after post-LT NET recurrence, particularly in those patients recurring long after LT (>24 mo). An aggressive surgical treatment might result in a new chance of cure for a selected subgroup of patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|